ABSTRACT
Background Physical activity (PA) in pre-clinical rheumatoid arthritis (RA) is associated with lower RA risk and disease severity. Yet, PA in RA patients is less than in counterparts without RA, which can be attributed partly to symptoms of inflammatory arthritis. Therefore, we investigated whether joint swelling, stiffness, or pain were associated with PA in first-degree relatives (FDRs) of RA patients, a population at higher risk for future RA.
Methods We evaluated associations of joint stiffness, joint swelling, and joint pain with PA time in 268 FDRs with ≥2 visits over an average 1.2 years. Clinicians confirmed joint swelling. Participants self-reported joint stiffness and/or pain. PA during a typical 24-hour day was quantified via questionnaire, weighted to reflect metabolic expenditure, where 24 hours was the minimum PA time. Linear mixed models evaluated associations between symptoms and change in PA over time, adjusting for age, sex, race, body mass index, smoking, and RA-related autoantibodies.
Results Average weighted PA time was 37±7 hours. In cross-sectional analysis, PA time was 1.3±0.9 hours higher in FDRs reporting joint pain (p=0.15); and 0.8±1.6 and 0.4±1 hours lower in FDRs with joint swelling (p=0.60) and stiffness (p=0.69), respectively. Longitudinally, adjusting for baseline PA time, baseline symptoms were not significantly associated with changes in PA time. However, on average over time, joint stiffness and pain were associated with lower PA time (pinteraction=0.0002, pinteraction=0.002), and joint swelling was associated with higher PA time (pinteraction<0.0001)
Conclusion Baseline symptoms did not predict future PA time, but on average over time, joint symptoms influenced PA time.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this research was made possible by grants from the Foundation for Physical Therapy Miami-Marquette Challenge Research Grant, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR051394-05), National Heart, Lung, and Blood Institute (K01HL122394), and National Institute for Diabetes and Digestive and Kidney Diseases (K24DK110427) at the National Institutes of Health, the ACR Rheumatology Research Foundation Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign and the Career Development Bridge Funding Award: K Bridge, and the Autoimmunity Prevention Center (U19 AI050864-10) at the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of California, San Diego Human Subjects Protection Program
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FINANCIAL DISCLOSURES The authors have no financial support from commercial sources or conflicts of interest to disclose.
Data Availability
Data used for this analysis will be provided upon request.
